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Rare heterozygous ALPK3 variants were also assessed in adult-onset cardiomyopathy patients. Among 1548 Dutch patients
referred for initial genetic analyses, we identified 39 individuals with rare heterozygous ALPK3 variants (2.5%; 95% CI: 1.8%-
3.4%), including 26 missense and 10 LoF variants. Among 149 U.S. patients without pathogenic variants in 83
cardiomyopathy-related genes, we identified six missense and nine LoF ALPK3 variants (10.1%; 95% CI: 5.7%-16.1%). LoF
ALPK3 variants were increased in comparison to matched controls (Dutch cohort, P = 1.6×10−5; U.S. cohort, P = 2.2×10−13).
Conclusion Biallelic damaging ALPK3 variants cause pediatric cardiomyopathy manifested by DCM transitioning to
hypertrophy, often with poor contractile function. Additional extracardiac features occur in most patients, including
musculoskeletal abnormalities and cleft palate. Heterozygous LoF ALPK3 variants are enriched in adults with cardiomyopathy
and may contribute to their cardiomyopathy. Adults with ALPK3 LoF variants therefore warrant evaluations for
cardiomyopathy. (Am Heart J 2020;225:108-119.)Pediatric-onset of cardiomyopathy, a disease of the
heart muscle causing systolic and/or diastolic dysfunc-
tion, is a devastating cause of heart failure in children and
the most common indication for heart transplantation in
children over 12 months of age.1 Onset occurs prenatally,
at birth, or throughout childhood. Damaging variants in
more than 100 genes cause either isolated or syndromic
pediatric cardiomyopathy through many different path-
ological mechanisms.2-4 ALPK3 (MIM 617608) is a
recently identified pediatric cardiomyopathy gene that
encodes alpha-protein kinase 3 (ALPK3), a protein with
functions that remain incompletely understood. ALPK3
participates in normal intercalated disc formation and
sarcomere organization in both humans and mice.5-7
Alpk3-null mice develop a non-progressive cardiomyop-
athy characterized by predominantly myocardial hyper-
trophy and diminished systolic function, as typically
occurs in dilated cardiomyopathy (DCM).6 Cardiomyo-
cytes derived from human-induced pluripotent stem cell
(hiPSC-CMs) lacking ALPK3 display abnormal calcium
handling.7
We previously reported seven patients from four
unrelated consanguineous families with pediatric cardio-
myopathy caused by biallelic predicted protein-
truncating (loss-of-function, LoF) variants in ALPK3.5,7
Two additional case reports described severe congenital
cardiomyopathy including features of both DCM and
hypertrophic cardiomyopathy (HCM) from homozygous
ALPK3 LoF variants.8 , 9 Extracardiac manifestations
have also been observed, including multiple pterygia
with skeletal muscle underdevelopment, facial dys-
morphisms, and skeletal features.7-9
Unlike affected children, the clinical phenotypes of
parents and relatives who carry only one damaging
ALPK3 allele are less penetrant. Three of 21 published
heterozygous carriers from two families had clinical
features of HCM, described as hypertrophy of the
interventricular septum,5,9 whereas other heterozygous
carriers had no cardiac disease. It is currently unclear ifthese observations indicate that damaging ALPK3 vari-
ants contribute to unexplained cardiomyopathy or
modify cardiomyopathy that is caused by a pathogenic
or likely pathogenic variant in an established disease
gene. To address these issues, we delineated the clinical
and genetic spectrum of patients with damaging biallelic
ALPK3 variants and defined the prevalence of heterozy-
gous ALPK3 variants in two cohorts with adult-onset
cardiomyopathy.Methods
Patient recruitment
Our study was carried out in collaboration with
clinicians from seven different countries and institutions.
Mutation analysis was performed using next-generation
sequencing (NGS), either whole exome sequencing or
targeted gene panels. Details on sequencing methods and
data analysis are available in the Data Supplement. We
reviewed clinical data of 19 patients with biallelic variants
in ALPK3 (NM_020778.4), including nine previously
reported patients.5,7-9 HCM was defined as increased
ventricular wall thickness (end diastolic wall thickness: z-
score ≥2) not solely explained by abnormal loading or
structural heart conditions such as valve disease, congen-
ital heart disease, or hypertension. DCM was defined as
ventricular dilation (LV end-diastolic dimension N2 SD
above mean for body surface area) and systolic dysfunc-
tion (fractional shortening or LV ejection fraction N2 SD
below mean for age) in the absence of abnormal loading
conditions.10,11 Chromosomal analysis was performed in
all index patients with pediatric-onset cardiomyopathy—
except patient F10P1. The Medical Research Ethical
Committees of the University Medical Center Groningen,
the Erasmus University Medical Center, Brigham and
Women's Hospital, and Boston Children's Hospital
approved this study. Informed consent was obtained
from all participants or their legal guardians.
This work was supported by the Dutch Heart
Foundation (grant number 2014 T007 to I.M.B.H.v.d.L.)
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Month Yearand an Erasmus University Rotterdam Fellowship (I.M.B.
H.v.d.L.), the National Health and Medical Research
Council/Heart Foundation (grant number G 12 M 6401
to P.J.L.), the Instituto de Salud Carlos III, Centro de
Investigación Biomédica en Red Enfermedades Cardio-
vasculares (grant numbers PIS15/02229, BA16/00032 to
R.Y.), the National Institutes of Health (grant numbers
5HL084553, 5HL080494, and UMIHG008900 to J.G.S. and
C.E.S., F30HL147389 to R.A., and HL129069 to M.A.B),
the American Heart Association Career Development
Award (A.H.), the Leducq Foundation (J.G.S. and C.E.S),
the Broad Center for Mendelian Genomics and the
Howard Hughes Medical Institute (C.E.S.), the Victorian
Government's Operational Infrastructure Support Pro-
gram and Australian Government National Health and
Medical Research Council Independent Research Insti-
tute Infrastructure Support Scheme (NHMRC IRIISS). P.J.
L. is supported by the Vincent Chiodo Foundation. The
authors are solely responsible for the design and conduct
of this study, all study analyses, the drafting and editing of
the manuscript, and its final contents.Variant interpretation
The pathogenicity of variants was assessed using
Alamut Visual software (Interactive Biosoftware,
Rouen, France), a gene browser that integrates missense
prediction tools (Align GVGD, SIFT, MutationTaster,
PolyPhen-2), allele frequencies from different population
databases (gnomAD,12 ESP, GoNL13) and disease-specific
databases (HGMD, ClinVar, LOVD) and mRNA splicing
prediction tools (SpliceSiteFinder-like, MaxEntScan,
NNSPLICE, GeneSplicer, and Branch Points). A potential
splice effect was defined as a difference between
reference and mutated scores greater than 10% reported
by three or more of five mRNA splicing prediction tools.
Deleteriousness of variants was scored using combined
annotation dependent depletion (CADD).14 A scaled
CADD score of 10, 20, or 30 indicates the top 10%, 1%,
and 0.1% most deleterious substitutions in the human
genome, respectively. Variants were interpreted accord-
ing to the 2015 ACMG guidelines.15 Variants with a
minor allele frequency (MAF) b0.1% in the Genome
Aggregation Database (gnomAD) dataset (considering
total population and major subpopulations) were con-
sidered rare. Nonsense and frameshift variants were
considered null variants, with the exception of those
residing in the last exon or the last 50 base pairs of the
penultimate exon.Protein multiple sequence alignments
We constructed ALPK3 multiple sequence alignments
over a fixed phylogeny of species: human,Hominidae (Pan
troglodytes), Glires (Mus musculus), Laurasiatheria (Bos
taurus), Marsupialia (Sarcophilus harrisii), Aves (Anasplatyrhynchos), and Teleostei (Xiphophorus maculatus,
Danio rerio). Sequences were aligned using T-Coffee.
Histology
Paraffin-embedded or frozen cardiac tissue was avail-
able for two affected individuals (patient 1 from family 1
(F1P1) and patient 2 from family 2 (F2P2); pedigrees 1
and 2, Data Supplement). In addition, we collected
muscle biopsy specimens from the lateral portion of the
quadriceps femoris muscle from patient 3 from family 2
(F2P3; pedigree 2, Data Supplement) and her healthy
sister (pedigree 2, Data Supplement) and from the spine,
taken at scoliosis surgery, from patient 1 from family 3
(F3P1; pedigree 3, Data Supplement). Tissues from age-
matched donors were used as controls. All samples were
histologically examined after hematoxylin and eosin
staining using standard techniques. Samples from patient
F3P1 were also examined by electron microscopy.
Cohort screening
ALPK3 was evaluated as part of a targeted NGS panel
(gene panels B, E or F, Supplementary Table II) in 1548
patients (suspected of) having cardiomyopathy who
were referred for diagnostic genetic testing at two
molecular diagnostic laboratories in the Netherlands
between December 2015 and July 2018. ALPK3 was
also evaluated from whole exome sequence data
obtained for 149 unrelated U.S. patients of European
ancestry who had clinically diagnosed HCM or DCM. In
each of these patients, prior NGS analyses of 83
established or putative cardiomyopathy genes (gene
panel G, Supplementary Table II) had excluded a
pathogenic or likely pathogenic variant. Co-segregation
analysis was performed for available family members in
both of these cohorts.Haplotype analysis
To investigate whether the recurrent c.4736-1G N A, p.
(Val1579Glyfs*30) variant originated from a single muta-
tional event, haplotype analysis was performed using 13
microsatellite markers surrounding ALPK3. DNA from six
probands (one homozygous carrier (F1P1) and five
heterozygous carriers) was analyzed, and DNA samples
of three family members of F1P1 who carry the variant
were used to verify the phase and reconstruct the
haplotype.
Statistical analysis
Sequence data of 64,000 unrelated Non-Finnish Euro-
peans (NFE, assembled by gnomAD) were used as an
independent control dataset. Raw data (version 2.1) were
downloaded and filtered on PASS quality status. ALPK3
variants with a MAF N0.1% (2000 alleles) were excluded.
The calculation of burden for LoF variants in cardiomy-
opathy cohorts and gnomAD subjects excluded LoF
Table I. Characteristics of 19 patients with biallelic ALPK3
variants.
Proportion %
Male 9/19 47%
Age of onset of CMP
Prenatal 4/19 21%
b1 year 10/19 52%
1-18 years 3/19 16%
18+ year 2/19 11%
Mutation type
LoF/LoF 11/19 58%
LoF/missense 7/19 37%
Missense/missense 1/19 0.5%
Progression DCM to LVH 8/18 44%
Prolonged QTc 13/16 81%
Endpoint
ICD 4/19 21%
HTx 2/19 11%
Death 4/19 21%
Short stature 9/15 60%
Kyphoscoliosis 6/15 40%
Webbed neck
Joint contractures
8/17
8/19
47%
42%
Cleft palate/VPI 8/18 44%
CMP = cardiomyopathy; DCM = dilated cardiomyopathy; LVH = left ventricular
hypertrophy; LoF = loss-of-function; ICD = implantable cardioverter defibrillator;
HTx = heart transplantation; VPI = velopharyngeal insufficiency.
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ALPK3 variants were expressed as proportions (exact
95% binomial confidence intervals [CI]). Differences in
prevalence rates between cohorts were estimated as the
risk difference with the exact 95% confidence interval of
the risk difference and statistically compared using a one-
tailed binomial test. Values of P b.05 were considered
significant.Results
Identification of ALPK3 sequence variants
All nine previously reported patients carried biallelic
LoF variants in the ALPK3 gene. Of the 10 new patients
described here, two carried biallelic ALPK3 LoF variants:
patient F7P3 (a distant relative of F7P1 and F7P2) carried
c.1018C N T, p.(Gln340*) and c.4332delC, p.
(Lys1445Argfs*29) and patient F12P1 was homozygous
for c.3418C N T, p.(Gln1140*). Seven patients (F7P1,
F7P2, F8P1, F9P1, F10P1, F10P2 and F11P1) had
compound heterozygous LoF and missense ALPK3
variants (Tables I and II and Supplementary Table I).
Patient F13P1 carried a homozygous missense variant,
c.5155G N C, p.(Ala1719Pro), which alters an alanine
residue within the alpha-kinase domain. The Ala1719Pro
substitution was absent in public exome databases and is
predicted to be damaging by SIFT and PolyPhen-2.
Identified ALPK3 variants did not cluster (Figure 1).
The alpha-kinase domain has high sequence identityamong ALPK family members and is required for
phosphate modification of other proteins, a fundamental
process involved in most signaling and regulatory
processes within eukaryotic cells.16 No additional likely
pathogenic or pathogenic variants in genes associated
with cardiomyopathy, including TTN, nor any pathogenic
copy number variants explaining their cardiomyopathy
were identified in any of the patients with biallelic
ALPK3 variants (Data Supplement and Supplementary
Table II). All but two ALPK3 missense variants had high
CADD scores (N 20; Table II), and most of the novel
amino acids substituted residues are highly conserved
across species (Data Supplement). In contrast, the p.
(Val812Met) variant in F7P1 and F7P2 had a low CADD
score and showed conflicting predictions of pathogenic-
ity. However, the phenotype of both siblings carrying this
variant (and a LoF variant on the other allele) showed
striking similarities with other patients with biallelic
ALPK3 variants. The p.(Glu199Asp) variant identified in
patients F10P1 and F10P2 had a low CADD score and is
also a conservative amino acid substitution that may not
impact secondary protein structure given the similar
properties of these residues (Grantham score: 45). While
this missense variant altered a residue within a region of
poor sequence alignment, thereby limiting assessment of
evolutionary conservation, the variant is absent from
gnomAD. Based on the shared phenotype exhibited by
F10P1, F10P2, and other carriers of biallelic ALPK3
variants, we suggest that p.(Glu199Asp) is also damaging.
However, functional studies should be carried out to
further support our hypothesis.Clinical features of patients with biallelic ALPK3
sequence variants
Table I and Supplementary Tables I and III provide
clinical summary data for the 19 patients (9 male), and
additional descriptions are provided in the Data Supple-
ment. The age at diagnosis of cardiomyopathy ranged
from 20 weeks of gestation to 53 years; two patients were
diagnosed after the age of 18 years. Among patients with
biallelic LoF variants, median age at diagnosis was 7 days
(range: 20 weeks gestation to 9 years). Median age at
diagnosis in patients carrying a LoF and a missense variant
was 3 months; two of them were diagnosed as adults
(range birth to 53 years). Patient F13P1, harboring two
missense variants, presented with cardiomyopathy at 35
weeks of gestation.
Prenatal findings were available for 16 patients and
included increased nuchal folds and/or fetal hydrops in
six patients (37.5%; 95% CI: 15.2%-64.6%). Eight of 18 live-
born patients (44.4%; 95% CI: 21.5%-69.2%), including
four with a LoF and a missense variant, showed left
ventricular or biventricular DCM in the neonatal period
that transitioned to ventricular hypertrophy at a later
stage (Figure 2A-B and Figure 3). Three patients who died
Table II. Overview of previously published (F1-F6) and novel biallelic variants in ALPK3.
Patient Nucleotide change Protein change Location gnomAD Splice prediction SIFT PolyPhen-2 CADD
F1P1 (homozygous) c.4736-1G N A p.
(Val1579Glyfs⁎30)
intron 9 4/
273120
Loss acceptor
site
NA NA 34
F 2 P 1 , F 2 P 2 , F 2 P 3
(homozygous)
c.3781C N T p.(Arg1261⁎) exon 6 8/
235216
No effect NA NA 35
F3P1 (homozygous) c.5294G N A p.(Trp1765⁎) exon 12 Absent No effect NA NA 46
F4P1, F4P2 (homozygous) c.3792G N A p.(Trp1264⁎) exon 6 Absent No effect NA NA 35
F5P1 (homozygous), F11P1
(comp. het.)
c.2023delC p.
(Gln675Serfs⁎30)
exon 5 5/
238584
No effect NA NA NA
F6P1 (homozygous) c.1531_1532delAA p.
(Lys511Argfs⁎12)
exon 5 Absent No effect NA NA NA
F7P1, F7P2, F7P3 (comp. het.) c.1018C N T p.(Gln340⁎) exon 4 Absent No effect NA NA 38
F7P1, F7P2 (comp. het.) c.2434G N A p.(Val812Met) exon 6 5/
277136
No effect Tolerated Probably
damaging
2.206
F7P3 (comp. het.) c.4332delC p.
(Lys1445Argfs⁎29)
exon 6 Absent No effect NA NA 38
F8P1 (comp. het.) c.541delG p.
(Ala181Profs⁎130)
exon 1 5/29436 No effect NA NA NA
F8P1 (comp. het.) c.3439C N T p.(Arg1147Trp) exon 6 15/
243424
No effect Deleterious Probably
damaging
19.77
F9P1 (comp. het.) c.4997delA p.
(Asn1666Thrfs⁎14)
exon 10 1/
245986
No effect NA NA NA
F9P1 (comp. het.) c.4091G N C p.(Gly1364Ala) exon 6 17/
269654
No effect Deleterious Probably
damaging
26.9
F10P1, F10P2 (comp. het.) c.5105+ 5G N C p.(?) intron
11
Absent Loss donor site NA NA 20.2
F10P1, F10P2 (comp. het.) c.597G N T p.(Glu199Asp) exon 1 Absent No effect Tolerated Benign 11.42
F11P1 (comp. het.) c.4888G N T p.(Val1630Phe) exon 10 Absent No effect Deleterious Probably
damaging
29.6
F12P1 (homozygous) c.3418C N T p.(Gln1140⁎) exon 6 Absent Loss cryptic
donor site
NA NA 33
F13P1 (homozygous) c.5155G N C p.(Ala1719Pro) exon 12 Absent No effect Deleterious Probably
damaging
29.5
⁎CADD = Combined Annotation Dependent Depletion v1.4; comp. het. = compound heterozygous; gnomAD = Genome Aggregation Database v2.0; NA = not available;
PolyPhen-2 = Polymorphism Phenotyping v2; SIFT = Sorting tolerant from intolerant. For variant annotation, human genome assembly GRCh37/hg19 and RefSeq NM_020778.4
was used.
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mixed phenotype of hypertrophy and DCM. Patient
F13P1 showed marked changes in cardiac morphology,
presenting with mild to moderate biventricular hypertro-
phy at birth that rapidly progressed to biventricular
dilated ventricles without hypertrophy. At age 2 years,
the DCM had again transitioned to left ventricular
hypertrophy (LVH). Among 16 surviving patients (age
N2 years), all (except patient F8P1) had LVH (93.8%; 95%
CI: 69.8%-99.8%), and eight patients (age N11 months)
also had right ventricular hypertrophy (50%; 95% CI:
24.7%-75.3%). Imaging studies showed progressive LVH
in seven of 13 patients (53.8%; 95% CI: 25.1%-80.8%).
Echocardiography of patient F4P1 demonstrated features
of left ventricular noncompaction (LVNC), and patients
F7P1 and F12P1 exhibited LVNC in association with LVH.
Patient F9P1 was diagnosed with HCM at 53 years of age
based on the finding of midventricular hypertrophy, a
morphology that was also observed in three heterozygous
carriers in family 3 (pedigree 3 in the Data Supplement).None of the patients with biallelic variants had a
structural heart defect (0/18; 95% CI: 0.0%-18.5%).
Electrocardiograms were available for 16 patients and
showed ventricular voltages consistent with biventricular
hypertrophy or LVH, repolarization abnormalities (infer-
olateral ST depression), and prolonged QT intervals likely
due to LVH (Figure 2D and Supplementary Table III). A
short PR-interval was noted in two siblings, as is seen in
Pompe disease (12.5%; 95% CI: 1.6%-38.3%) (Figure 2C).
Rhythm and conduction disorders occurred in seven
patients (43.8%; 95% CI:19.8%-70.1%). These included
supraventricular tachycardia (n = 2), nonsustained ven-
tricular tachycardia (n = 2), premature ventricular con-
tractions (n = 1), ventricular fibrillation (n = 2),
intraventricular conduction delay (n = 1), and second-
degree atrioventricular block (n = 1). Four patients
received an implantable cardioverter defibrillator (25%;
95% CI: 7.3%-52.4%), and two had a heart transplant at the
ages 4 and 28 years, respectively (12.5%; 95% CI:1.6%-
38.3%).
Figure 1
Schematic representation of the structure of ALPK3 gene (top) and protein and location of disease-associated variants.
The ALPK3 gene is located on chromosome 15q25 and encodes a member of a superfamily of protein kinases. ALPK3 contains three domains: an
alpha-type protein kinase domain and two Ig-like domains. Homozygous variants are displayed on the top of the diagram. Compound
heterozygous variants are displayed on the bottom of the diagram. Premature stop codon–introducing variants are indicated in red.
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hydrops) was observed in 16 of 18 (88.9%; 95% CI: 65.3%-
98.6%) live-born patients with damaging biallelic ALPK3
variants. At birth all patients were at normal size for their
gestational age, but their subsequent growth was
delayed. The height of 9/15 patients (60%; 95% CI:
32.3%-83.7%) ranged from 2 to 6 SDs below the normal
mean.
Musculoskeletal abnormalities were observed in 11/
18 patients (61.1%; 95% CI: 35.7%-82.7%), including
severe scoliosis (n = 6) (Figure 4A), webbed neck (n =
8) (Figure 4B), knee and/or shoulder contractures (n =
5), camptodactyly/arthrogryposis (n = 6) (Figure 4C),
and spondylolysis (n = 2). Five patients had congenital
contractures, while one patient developed contractures
and scoliosis later in life. Four of 12 patients (33.3%;
95% CI: 9.9%-65.1%) had delayed motor development
with independent walking at ages 18 to 32 months, and
three of these children also had a speech delay. Patient
F3P1, now aged 14 years, has a learning disorder
(nonverbal IQ 74). Hypotonia was present in 4/13
patients (30.8%; 95% CI: 9.1%-61.4%). Cleft palate or
velopharyngeal insufficiency occurred in 8/18 patients
(44.4%; 95% CI: 21.5%-69.2%). Craniofacial dysmorphic
features were present in at least 12/17 patients (70.6%;
95% CI: 44.0%-89.7%), including hypertelorism, ptosis,
ankyloglossia, intra-oral pterygia, micrognathia, and
low-set ears (Figure 4B). At least 3/12 patients (25.0%;
95% CI: 5.5%-57.2%) had abnormal glucose metabolism.
We observed no significant association between the
variant type or location and the severity of extracardiac
phenotypes.Clinical features of patients' relatives with heterozygous
ALPK3 variants
Among previously published families, five heterozy-
gous carriers of an ALPK3 LoF allele showed LVH: three
members of family 3 exhibited midventricular hypertro-
phy at ages 27, 29, and 64, respectively; the father of
patient F5P1 was diagnosed with HCM at age 30; and the
father of patient F6P1 had asymmetric hypertrophy of the
interventricular septum (5/22; 22.7%; 95% CI: 7.8%-
45.4%). Cardiac evaluations were normal in 17 other
clinically evaluated relatives with heterozygous LoF
ALPK3 variants (17/22; 77.3%; 95% CI: 54.6%-92.2%).
Among our newly studied families, none of 20 obligatory
heterozygous carriers of a damaging ALPK3 variant have
cardiomyopathy or extracardiac abnormalities (0%; 95%
CI: 0.0%-16.8%). As the prevalence of unexplained LVH in
the general population is 0.10%,17 finding LVH in five of
37 (13.5%; 95% CI: 4.5%-28.8%) heterozygous ALPK3 LoF
carriers is unexpected (difference, 13.4 percentage
points; 95% CI: 4.4-28.7; P = 4.2×10−10). Although we
cannot fully exclude a shared inherited modifier or
private mutations in yet unknown HCM genes in these
families as an explanation for the LVH, this observation
suggests a causal relationship between carrying a
heterozygous ALPK3 LoF variant and LVH.Histopathologic examination
Post-mortem microscopic examination of myocardial
tissue showed (sub)endocardial fibro-elastosis in patients
F1P1, F2P1, F5P2, and F5P3. At the DCM stage, no
myofiber disarray was observed (patient F1P1). Histopa-
thology of patient F2P1, who had both ventricular
Figure 2
Echocardiographic images and ECGs.Cardiac ultrasounds of patient F10P1: (A) initial presentation with decreased function (shortening
fraction 9.4%) and (B) at 11 years of age showing shortening fraction of 36.2%. Initial/final z-scores for IVSd and LVPWd are 2.4/4.7 and 2.64/
7.2, respectively. C, ECG of patient F10P1 at age 11 years showing short PR interval (94 ms), short QRS duration (62 ms), marked left ventricular
hypertrophy with repolarization abnormality, and prolonged QTc (497 ms), which may be due to QRS abnormality. D, ECG of patient F13P1 at
age 3.5 years showing atrial enlargement, marked biventricular hypertrophy, repolarization abnormalities, and prolonged QTc, which is likely
secondary to LVH.
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hypertrophy without myofiber disarray. Patients F7P2
and F7P3 underwent cardiac biopsy at age 4 years and 28
years, respectively, when their DCM progressed to
biventricular hypertrophy. Cardiac histopathology of
patient F7P3 showed cardiomyocyte hypertrophy with
myofiber disarray. A spinal muscle biopsy of patient F3P1
taken at scoliosis surgery showed variation in fiber size,
fiber splitting, and numerous central cores (Figure 5A and
B). However, subsequent examination of the quadriceps
muscle of the same patient did not show any ultrastruc-
tural abnormalities (Figure 5C).
Burden of heterozygous LoF ALPK3 variants identified
in patients with adult-onset cardiomyopathy
We assessed the prevalence of ALPK3 variants in two
independent cardiomyopathy cohorts. The Dutch cohort
comprised 1548 index patients with predominantly adult-
onset cardiomyopathy referred for clinical genetic
testing. None had biallelic damaging ALPK3 variants,but 24 rare (MAF b0.1%) heterozygous ALPK3 variants
were identified in 39 patients (2.5%; 95% CI: 1.8%-3.4%),
including four LoF variants (three frameshift and one
splice site variant resulting in exon 10 skipping), 18
missense variants, one stop gain variant in the last exon,
and one synonymous variant with a predicted effect on
splicing (Supplementary Table IV). Ten variants recurred
in more than one patient. The heterozygous c.4736-
1G N A, p.(Val1579Glyfs*30) variant initially observed in
the unaffected parents and sister of patient F1P1 also
occurred in five adult cardiomyopathy probands (P025-
P029) and four of 273,120 alleles (0.0015%) in gnomAD.
A shared haplotype consisting of 5 of 13 polymorphisms
located within 2.33 Mb flanking ALPK3 was identified in
eight individuals from five families, suggesting a common
founder in the Dutch population (Supplementary Table
V).
Patients with heterozygous ALPK3 variants (Supple-
mentary Table IV) had the following clinical diagnoses:
HCM (13 missense variants, 7 LoF variants, 2 stop gain
Figure 3
Transthoracic echocardiography images of patient F13P1. A-C, Echocardiographic images at DCM stage with very poor systolic
function—age 12 days. (A, systolic 4-chamber view; B, short axis view; C, parasternal long axis view). D‐F, Echocardiographic images of patient
F13P1 at HCM stage—age 4 years (D, 4-chamber view; E, short axis view; F, parasternal long axis view).
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predicted to affect splicing), DCM (6 missense, 2 LoF),
arrhythmogenic cardiomyopathy (ACM, 3 missense, 1
LoF), LVNC (1 missense), mixed/unspecified cardiomy-
opathy (2 missense), and one sudden cardiac death
with unknown cardiac disease (1 missense). Seven of
these patients (17.9%; 95% CI: 7.5%-33.5%) also had a
likely pathogenic or pathogenic variant in another
cardiomyopathy gene (Supplementary Table VI):
MYBPC3 (n = 4), MYH7 (n = 1), TNNI3 (n = 1), and
LMNA (n = 1).The frequency of ALPK3 LoF variants in the general
population approximates the expected frequency, when
accounting for protein size (pLI = 0.00; gnomAD12),
which implies that one null ALPK3 allele is tolerated. The
gnomAD dataset reports 2149 rare (MAF b0.1%) missense
or LoF ALPK3 alleles among ~64,000 NFE (3.4%; 95% CI:
3.2%-3.5%) compared to 38 in 1548 Dutch cardiomyop-
athy patients (2.5%; 95% CI: 1.7%-3.4%) (Supplementary
Table IV; difference, 0.91 percentage points; 95% CI: −
2.09%-1.63%; P = 0.024). In contrast, we observed
significantly more LoF ALPK3 alleles in Dutch
Figure 4
Extracardiac features in patients with biallelic ALPK3 variants. A, Anteroposterior X-ray demonstrating S-shaped scoliosis of the
thoracic and lumbar spine of patient F3P1. Note: cardiomegaly and implantable cardiac defibrillator in situ. B, Faces of patients F7P1, F11P1, and
F13P1. C, Distal arthrogryposis in patient F13P1: bilateral absent flexion creases of dig. V and congenital contractures of dig. I, II and V of the left
hand and dig. V of the right hand.
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1.2%) than in NFE (73/64,000; 0.11%; 95% CI: 0.1%-0.1%;
difference, 0.54 percentage points; 95% CI: 0.20-1.07;
P = 1.6×10−5).
The second cohort comprised 149 unrelated cardiomyop-
athy patients (HCM, n = 129; DCM, n = 20) of European
ancestry from the United States. Previous genetic analyses in
these patients had excluded a pathogenic or likely
pathogenic variant in 83 cardiomyopathy genes. Analyses
of exome sequencing data identified 15 rare (MAFb 0.1%)
ALPK3 protein–altering variants (15/149; 10.1%; 95% CI:
5.7%-16.1%) (Supplementary Table IV): 14 in HCM patients
(8 LoF and 6 missense variants) and one in a DCM patient (aLoF variant). No patients had biallelic variants and none of
the variants recurred in this cohort. Similar to what we
observed in the Dutch cohort, the proportion ofALPK3 LoF
variants in the U.S. cardiomyopathy cohort (9/149; 6.0%;
95% CI: 2.8%-11.2%) was significantly higher than in
gnomAD NFE (73/64,000; 0.11%; 95% CI: 0.09%-0.14%;
difference, 5.93 percentage points; 95% CI: 2.69-11.05; P =
2.2×10−13).Discussion
The clinical manifestations of biallelic and heterozy-
gous ALPK3 variants are quite distinct. Among 19 patients
Figure 5
Histopathologic examination of skeletal tissue. A, Electron microscopic (EM) examination of spinal muscle from patient F3P1: relatively
unaffected region (4000×). B, Central core (2200×, arrowhead). C, EM of quadriceps muscle sarcomeres from F3P1 showing regular arrangement
of contractile protein filaments (8900×).
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pound heterozygous variants, 17 patients presented with
pediatric-onset cardiomyopathy. Strikingly, most cases
presented initially with DCM that then transitioned to
ventricular hypertrophy with reduced systolic perfor-
mance—an unusual clinical sequence. ALPK3 cardiomy-
opathy often progressed rapidly and six patients died or
underwent cardiac transplantation. Most patients had
extracardiac manifestations, including craniofacial and
musculoskeletal abnormalities, but these were not
sufficiently consistent to delineate a recognizable
syndrome.
We report, for the first time, biallelic missense variants
that cause pediatric-onset cardiomyopathy. The clinical
manifestations associated with these variants were similar
to those associated with other damaging ALPK3 variants.
These missense variants could result in a conformational
change that affects protein folding or flexibility, protein-
protein or protein-DNA interaction, or the activity of the
alpha-kinase domain. Unfortunately, no 3D structure of
ALPK3 is available to predict the consequence of the
missense variants. In addition, we demonstrated higher
than expected frequencies of heterozygous ALPK3 LoF
variants among adult cardiomyopathy patients in a Dutch
and a U.S. cohort. Thirty-seven of these patients were
clinically diagnosed with HCM, which is likely related to
the hypertrophy phenotype observed in pediatric pa-
tients with biallelic ALPK3 variants. Despite this similar-
ity, there were other notable differences between the
clinical features associated with monoallelic and biallelic
ALPK3 cardiomyopathy, including absence or undetect-
ed extracardiac phenotypes. Whether these differences
reflect graded dose-responses to ALPK3 deficits or
distinct mechanisms by which monoallelic or biallelic
variants cause disease remains unknown.Biallelic ALPK3 variants were associated with a range
of morphological and functional abnormalities. Almost
half of the live-born pediatric patients presented with
DCM that later evolved into ventricular hypertrophy.
Three individuals initially displayed a mixed cardiomy-
opathy with features of both DCM and ventricular
hypertrophy that evolved into concentric hypertrophy
of both left and right ventricles.9 This hypertrophic
phenotype differs from classic HCM caused by pathogen-
ic variants in genes encoding sarcomere proteins.
Notably, hypertrophy was atypical, often biventricular
and/or concentric, or apical in distribution. LV dilatation
occurred in some pediatric patients, which occurs rarely
in HCM and usually decades after diagnosis, with
accompanying decrease in systolic performance.18,19
Like other pediatric cardiomyopathies, ALPK3 cardiomy-
opathy can present with features of more than one
subtype.20,21 However, transition from DCM to LVH has
not been described before and appears to be unique to
biallelic ALPK3 cardiomyopathy.
The histopathology of biallelic ALPK3 cardiomyopathy
has some features observed in classic HCM,22 including
focal cardiomyocyte hypertrophy, interstitial fibrosis and,
at adult age, myofiber disarray. Whether this histopathol-
ogy precedes the progression to hypertrophy remains
unclear. Patients with biallelic variants in ALPK3 display a
variety of rhythm and conduction disturbances reminis-
cent of those seen in arrhythmogenic cardiomyopathy.
We previously showed a reduced plakoglobin signal at
intercalated disks of patients with biallelic ALPK3
variants.5 A reduced plakoglobin signal has also been
documented in ACM23; this redistribution of plakoglobin
from the junctional pool to the intracellular and nuclear
pools likely suppresses the canonical Wnt/beta-catenin
signaling, leading to enhanced fibrogenesis and myocyte
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the same pathophysiological mechanisms, thus explain-
ing the arrhythmogenic phenotype in patients with
biallelic ALPK3 variants. Alternatively, the rhythm
disorders observed in ALPK3 cardiomyopathy may be
secondary to progressive disease.
We observed no association between extracardiac
manifestations and allelic heterogeneity: biallelic mis-
sense or LoF variants seemed to cause similar pheno-
types. The majority of patients with biallelic ALPK3
variants, including those with one or two missense
variants, had musculoskeletal involvement, including
contractures and severe progressive scoliosis. Several
patients had cleft palate, velopharyngeal insufficiency,
and/or facial dysmorphisms. Jaouadi et al also described
a patient with a diversified phenotype, including cleft
palate, pectus excavatum, bilateral clinodactyly, and
facial dysmorphic features like broad forehead, down-
slanting palpebral fissures, mild ptosis, and low-set
posteriorly rotated ears, which fits with the extracar-
diac features we observed in our cohort.9 While we
cannot exclude that genome-wide inbreeding contrib-
uted to the extracardiac features seen in patients with
homozygous ALPK3 variants, their occurrence in
multiple unrelated patients with different allelic vari-
ants and genetic backgrounds suggests direct effects of
ALPK3 variants.
The expression of ALPK3 helps to explain these
extracardiac phenotypes. The prevalence of skeletal
muscle phenotypes in pediatric patients likely reflects
ALPK3 expression in developing skeletal and heart
muscle6 ,24 and in adult skeletal, smooth, and heart
muscles (GTEx (https://commonfund.nih.gov/gtex)).
In embryonic mice (E8.5), Alpk3 expression is
detectable around the first branchial arch,24 which
may account for palatal abnormalities. Further support
for the syndromic nature of ALPK3-related disease
arises from GeneNetwork Assisted Diagnostic Optimi-
zation (GADO), a method that exploits RNA-seq data
from a range of tissues and cell types and uses gene co-
regulation to predict gene functions.25 For ALPK3,
GADO predicts “muscle contraction” and “myogen-
esis” as the top phenotypes. Based on a combination of
the major shared phenotypic abnormalities in our
patients, GADO ranked ALPK3 in the top 1% of all
coding and non-coding human genes (P = .000432)
(Supplementary Table VII).
Pathogenicity of heterozygous ALPK3 variants
Among 37 relatives with a heterozygous LoF variant
in ALPK3 (three ≤18 years of age), five (13.5%) were
diagnosed with HCM as adults. In line with this
finding, we note that gnomAD reports fewer ALPK3
L o F v a r i a n t s ( t r a n s c r i p t NM _ 0 2 0 7 7 8 . 4
(ENST00000258888)) than would be expected ifthese were to occur randomly, despite a pLI = 0.00.
While the observed and expected differences are not
statistically significant, we suggest that some individ-
uals with ALPK3 LoF may have an undetected mild or
late-onset cardiomyopathy.
To better understand the role of ALPK3 variants in
adult-onset cardiomyopathy, we analyzed two indepen-
dent patient cohorts. In both cohorts, the frequency of
ALPK3 LoF variants was significantly higher than in the
general population. Together these findings provide
compelling evidence that ALPK3 plays important roles
in cardiac function and pathologic remodeling. Further
evidence for the role of ALPK3 in cardiac hypertrophy
arises from a genome-wide association meta-analysis
that identified a novel locus at chromosome 15q25.3,
which encompasses ALPK3 and is strongly associated
with two clinically used QRS traits (Cornell and 12-lead
sum), reflecting a higher LV myocardial mass. One of
the lead SNPs in this GWAS is in strong linkage
disequilibrium with two nonsynonymous SNPs in
ALPK3 (P = 9.94e-18).26 Basic studies are now needed
to understand the targets and pathways in which this
kinase participates.Limitations
The majority of pediatric patients with biallelic
damaging ALPK3 variants were characterized in the
context of clinical care, and medical examinations,
imaging, and other laboratory studies were not
consistently obtained across all patients. Phenotypes
of heterozygous first-degree relatives from cardiac
screening, interviews, and/or medical records were
not systematically obtained. The mean coverage of
ALPK3 sequencing data in gnomAD is much lower
than in our cohorts, particularly for distal exon 1
sequences and exon 6. Therefore, the number of
va r i an t s repor ted in gnomAD may be an
underrepresentation.Conclusions
Our study reinforces the role of ALPK3 in pediatric
cardiomyopathy, and we describe a unique cardiac pheno-
type with progression of DCM to ventricular hypertrophy as
a major feature of ALPK3-related disease. We further show
that biallelic variants in ALPK3 can cause a syndromic form
of cardiomyopathy with musculoskeletal features as well as
craniofacial abnormalities. We also demonstrate an in-
creased burden of heterozygous ALPK3 LoF variants in
two adult-onset cardiomyopathy cohorts. Further study is
needed to establish the pathogenicity of heterozygous
ALPK3 variants.
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